The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Related Articles
Tandem CD20-CD19-Directed CAR T-Cell Therapy for Relapsed/Refractory DLBCL: Zamtocabtagene Autoleucel
Nirav Shah, MD, discusses findings from an interim analysis of the phase 2 DALY II trial, which is the first pivotal trial evaluating tandem CD20-CD19…
Webinars
Join us for upcoming webinars associated with AACR IO: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy
Joint Scientific Meeting
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,900 physicians, investigators and other health care professionals…
Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck
Nature Reviews Clinical Oncology – Accumulating evidence indicates that NUT carcinoma, a highly aggressive malignancy driven by NUTM1 fusions, is a rare form of squamous…
RFK Jr. Refuses to Say HPV Vaccine Is Safe
At today’s Senate Health, Education, Labor, and Pensions Committee hearing, nominee for Secretary of the Department of Health and Human Services Robert F. Kennedy (RFK)…
Fox Chase Cancer Center’s Austin Williams Named 2025 Society of Surgical Oncology Presidential Scholar
Austin D. Williams, MD, MSEd, FACS, was recently named a Presidential Scholar by the Society of Surgical Oncology.
Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS
Imetelstat is an oligonucleotide telomerase inhibitor recently approved by the US Food and Drug Administration for adults with lower-risk myelodysplasia wh
FDA approves Enhertu as first HER2-directed therapy for breast cancer – The Cancer Letter
FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic hormone receptor-positive, HER2-low (IHC 1+ or…
Myelofibrosis Disease Biology: From Molecular Mechanisms to Clinical Phenotypes and Therapeutic Targets
Panelists discuss how myelofibrosis progresses from its molecular and genetic origins through various clinical manifestations, ultimately informing the development of targeted therapeutic approaches for this…
